BioSpace News Archive

Forecast to 2030,’ thoroughly examines the Transverse Myelitis industry to provide essential data & information for the targeted readers.

Cingulate Inc. announced that Chief Financial Officer, Lou Van Horn, has been named a 2022 CFO of the Year by the Kansas City Business Journal.

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter of 2022 after the market closes on Monday, August 8, 2022.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that data from the company’s Phase 1 study of zanidatamab zovodotin (ZW49), an investigational novel bispecific HER2 targeted antibody-drug conjugate, were accepted for an oral presentation at the European Society for Medical Oncology Congress 2022 in Paris.

Theralink Technologies , Inc. (OTC: THER) (“Theralink” or the “Company”) , a precision oncology company with a novel phosphoprotein-based assay for breast cancer, today announced that it has acquired licenses for two new U.S. patents relating to methods for treating breast cancer: US 10,823,738 and US 10,690,672, expanding the Company’s patent portfolio to nine.

Applied DNA Sciences, Inc. today announced the publication of a manuscript containing data demonstrating that a linearDNA vaccine successfully elicited neutralizing antibodies and cellular immunity against SARS-CoV-2.

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced that Mehul Joshi has been named chief financial officer (CFO), effective immediately.

Forecast to 2030,’ thoroughly examines the Mastocytosis industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Pulmonary Fibrosis Treatment industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Supraventricular Tachycardia Treatment industry to provide essential data & information for the targeted readers.